Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | FABP7 | O15540 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151315 | 0.91 | NAMPT (0.35) | NAMPTHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL24974802 | 0.91 | NAMPT (0.32) | NAMPTFABP7 | |
| SCHEMBL24974528 | 0.90 | MAPK1 (0.33) | NAMPTHDAC1HDAC6TACR1MAPK1 | |
| SCHEMBL21151201 | 0.89 | MCHR1 (0.38) | NAMPTHDAC1HDAC6MAPK1CYP2D6 | |
| SCHEMBL21151136 | 0.88 | HDAC1 (0.33) | NAMPTHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21150845 | 0.87 | NAMPT (0.34) | NAMPTHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21151259 | 0.87 | NAMPT (0.34) | NAMPTHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21150858 | 0.86 | NAMPT (0.36) | NAMPTHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21151158 | 0.85 | NAMPT (0.33) | NAMPTHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21150848 | 0.85 | NAMPT (0.34) | NAMPTHDAC1HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | NAMPT 1356/4885HDAC1 2698/4885HDAC6 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.